{"title":"美国平价医疗法案对抑郁症结果影响的成本效益研究。","authors":"Babak Mohit","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Two separate changes in insurance regulation have altered mental health delivery to Americans: (i) the Mental Health Parity and Addiction Equity Act (MHPA 2008) and (ii) the Patient Protection and Affordable Care Act (ACA 2010). This study aims to model and provide estimates for the costs and effects of depression that are impacted by these regulations.</p><p><strong>Method: </strong>Literature exists on the effectiveness of insurance coverage in reducing the prevalence, the costs of treatment and lost productivity time, as well as the health related quality of life (HRQL) associated with depression. Data from this literature is employed in a Markov model to obtain costs and effects associated with depression under both the MHPA and the ACA regulations as compared to without either one.</p><p><strong>Results: </strong>The implementation of these regulations may reduce the per capita lifetime costs of depression treatment and lost productivity by USD 215 and enhance life expectancy by 0.01 Quality Adjusted Life Years (QALY) per capita.</p><p><strong>Conclusions: </strong>If the savings of these regulations are expanded over the entire cohort of Americans adults, the potential cost savings from treated depression are estimated at USD 47.30 billion in addition to 2.2 million QALYs saved.</p>","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"21 2","pages":"71-78"},"PeriodicalIF":1.0000,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Cost-effectiveness Study of the Impact of the Affordable Care Act on Depression Outcomes in the United States.\",\"authors\":\"Babak Mohit\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Two separate changes in insurance regulation have altered mental health delivery to Americans: (i) the Mental Health Parity and Addiction Equity Act (MHPA 2008) and (ii) the Patient Protection and Affordable Care Act (ACA 2010). This study aims to model and provide estimates for the costs and effects of depression that are impacted by these regulations.</p><p><strong>Method: </strong>Literature exists on the effectiveness of insurance coverage in reducing the prevalence, the costs of treatment and lost productivity time, as well as the health related quality of life (HRQL) associated with depression. Data from this literature is employed in a Markov model to obtain costs and effects associated with depression under both the MHPA and the ACA regulations as compared to without either one.</p><p><strong>Results: </strong>The implementation of these regulations may reduce the per capita lifetime costs of depression treatment and lost productivity by USD 215 and enhance life expectancy by 0.01 Quality Adjusted Life Years (QALY) per capita.</p><p><strong>Conclusions: </strong>If the savings of these regulations are expanded over the entire cohort of Americans adults, the potential cost savings from treated depression are estimated at USD 47.30 billion in addition to 2.2 million QALYs saved.</p>\",\"PeriodicalId\":46381,\"journal\":{\"name\":\"Journal of Mental Health Policy and Economics\",\"volume\":\"21 2\",\"pages\":\"71-78\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2018-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Mental Health Policy and Economics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Mental Health Policy and Economics","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
A Cost-effectiveness Study of the Impact of the Affordable Care Act on Depression Outcomes in the United States.
Objective: Two separate changes in insurance regulation have altered mental health delivery to Americans: (i) the Mental Health Parity and Addiction Equity Act (MHPA 2008) and (ii) the Patient Protection and Affordable Care Act (ACA 2010). This study aims to model and provide estimates for the costs and effects of depression that are impacted by these regulations.
Method: Literature exists on the effectiveness of insurance coverage in reducing the prevalence, the costs of treatment and lost productivity time, as well as the health related quality of life (HRQL) associated with depression. Data from this literature is employed in a Markov model to obtain costs and effects associated with depression under both the MHPA and the ACA regulations as compared to without either one.
Results: The implementation of these regulations may reduce the per capita lifetime costs of depression treatment and lost productivity by USD 215 and enhance life expectancy by 0.01 Quality Adjusted Life Years (QALY) per capita.
Conclusions: If the savings of these regulations are expanded over the entire cohort of Americans adults, the potential cost savings from treated depression are estimated at USD 47.30 billion in addition to 2.2 million QALYs saved.
期刊介绍:
The Journal of Mental Health Policy and Economics publishes high quality empirical, analytical and methodologic papers focusing on the application of health and economic research and policy analysis in mental health. It offers an international forum to enable the different participants in mental health policy and economics - psychiatrists involved in research and care and other mental health workers, health services researchers, health economists, policy makers, public and private health providers, advocacy groups, and the pharmaceutical industry - to share common information in a common language.